Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Hdl Handle:
http://hdl.handle.net/10147/323888
Title:
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Authors:
Sequist, Lecia V; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin
Affiliation:
Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Citation:
Sequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013, 31 (27):3327-34 J. Clin. Oncol.
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue Date:
20-Sep-2013
URI:
http://hdl.handle.net/10147/323888
DOI:
10.1200/JCO.2012.44.2806
PubMed ID:
23816960
Abstract:
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
Item Type:
Article
Language:
en
Keywords:
LUNG CANCER; CHEMOTHERAPY
MeSH:
Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, Epidermal Growth Factor
ISSN:
1527-7755

Full metadata record

DC FieldValue Language
dc.contributor.authorSequist, Lecia Ven_GB
dc.contributor.authorYang, James Chih-Hsinen_GB
dc.contributor.authorYamamoto, Nobuyukien_GB
dc.contributor.authorO'Byrne, Kennethen_GB
dc.contributor.authorHirsh, Veraen_GB
dc.contributor.authorMok, Tonyen_GB
dc.contributor.authorGeater, Sarayut Lucienen_GB
dc.contributor.authorOrlov, Sergeyen_GB
dc.contributor.authorTsai, Chun-Mingen_GB
dc.contributor.authorBoyer, Michaelen_GB
dc.contributor.authorSu, Wu-Chouen_GB
dc.contributor.authorBennouna, Jaafaren_GB
dc.contributor.authorKato, Terufumien_GB
dc.contributor.authorGorbunova, Veraen_GB
dc.contributor.authorLee, Ki Hyeongen_GB
dc.contributor.authorShah, Riyazen_GB
dc.contributor.authorMassey, Danen_GB
dc.contributor.authorZazulina, Victoriaen_GB
dc.contributor.authorShahidi, Mehdien_GB
dc.contributor.authorSchuler, Martinen_GB
dc.date.accessioned2014-07-29T09:20:11Z-
dc.date.available2014-07-29T09:20:11Z-
dc.date.issued2013-09-20-
dc.identifier.citationSequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013, 31 (27):3327-34 J. Clin. Oncol.en_GB
dc.identifier.issn1527-7755-
dc.identifier.pmid23816960-
dc.identifier.doi10.1200/JCO.2012.44.2806-
dc.identifier.urihttp://hdl.handle.net/10147/323888-
dc.description.abstractThe LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subjectLUNG CANCERen_GB
dc.subjectCHEMOTHERAPYen_GB
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCisplatin-
dc.subject.meshFemale-
dc.subject.meshGlutamates-
dc.subject.meshGuanine-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMutation-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.titlePhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.en_GB
dc.typeArticleen
dc.contributor.departmentLecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.en_GB
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.